Strategies to Target HER2 in Lung Cancer Published 2021-01-22 Download video MP4 360p Recommendations 03:46 Understanding Immunotherapy for Lung Cancer 04:33 The HER Pathway and Cancer 05:53 Targeted Therapy in Non-Small Cell Lung Cancer 01:41 How Long Do You Live With Stage 4 Lung Cancer? | Lung Foundation Australia 03:10 Lung Cancer Staging Non-Small Cell 05:01 What to Expect After Diagnosis—TAGRISSO® (osimertinib) 03:24 'Tumors just vanished': Cancer patients now in remission after drug trial 58:27 Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies 47:57 Lung Cancer New Treatment 2023 03:09 HER2 in Cancer 02:18 EGFR-Mutant Lung Cancer: A Patient's Journey 31:51 Lung Cancer Breakout: Breakthrough treatments for longer life 03:30 Immunotherapy Treatments for Non-Small Cell Lung Cancer (NSCLC) 04:23 Understanding mutations in lung cancer 20:01 Can we eat to starve cancer? - William Li 02:29 Understanding Lung Cancer Survival Rate 02:22 Combination Therapy Increases Survival in Metastatic Lung Cancer Patients 06:18 Treating HER2 Exon-20 Insertion NSCLC with Trastuzumab Deruxtecan - Case Based Panel Discussion 56:23 Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and Others Similar videos 01:13 Challenges to Targeting HER2 in Lung Cancer 02:22 Dr. Pennell on the Evolution of Targeting HER2 in Lung Cancer 03:26 Lung Cancer Diagnosis: HER2 Mutation 1:01:05 Treatment strategies and sequencing for people living with mutation positive lung cancer 02:54 HER2 Mutation Positive NSCLC 1:25:12 A Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2+ Breast Cancer 02:23 Therapeutic strategies for EGFR-mutated lung cancer 33:28 Novel targeted therapies for NSCLC: Exploring HER2 dysregulation 1:02:50 New Strategies in Lung Cancer: Innovations in Clinical Trials, Treatments, and Patient Care 57:49 Understanding HER2 Alterations in Advanced Non-Squamous NSCLC 02:24 Dr. Reckamp on MET-Targeting Strategies in NSCLC 18:41 Extreme Rare Mutations in Lung Cancer (ROS1, TRK, HER2): Treatment opportunities More results